Ceva Animal Health Ltd (Great Britain) has announced the launch of Cirbloc M Hyo, a new ready‑to‑use dual‑action vaccine designed to protect pigs against Porcine Circovirus Type 2 (PCV2) and Mycoplasma hyopneumoniae (M.hyo).
The Cirbloc M Hyo vaccine formulation contains a PCV2d genotype, the most prevalent genotype circulating in the field, offering protection against all relevant PCV2 genotypes (PCV2a, b and d). It is combined with Ceva’s proprietary Mycoplasma hyopneumoniae strain (2940), which is already being used successfully by producers when vaccinating with Hyogen.
The vaccine provides 23 weeks duration of immunity for both PCV2 and M.hyo, thereby helping to reduce respiratory disease, support herd stability and maintain consistent health across batches and seasons, Ceva said.
To help demonstrate its benefits in the field, Ceva will be offering and implementing the Ceva Lung Program, which provides producers with important and detailed pig lung health and economic performance analysis.
The company said the vaccine enables producers to simplify their vaccination programmes and reduce piglet handling, a ‘practical approach that supports efficient routine management while meeting the day‑to‑day and long-term health needs of the herd’.
“The launch of Cirbloc M Hyo reinforces Ceva’s long‑term commitment to delivering innovative solutions for the pig industry. Ceva’s expertise in dual‑action products is well established, with Forceris already providing early‑life health benefits for several years,” the company said.
The Ceva swine team will officially introduce the new vaccine at this week’s Pig & Poultry Fair (Hall 20, Stand 753). “Visitors are warmly invited to stop by for a coffee to learn more and explore Ceva’s full range of vaccines, diagnostic tools, and technical support,” Ceva said.